Acquired Secondary RAS Mutation in BRAF^V600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.

ABSTRACT: Background: The BRAF^V600E mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAF^V600E-mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAF^V600E-mutated PTC. However, as with all targeted therapies, resistance to these drugs eventually develops. It is essential that we understand the mechanisms of resistance to the BRAF inhibitors in thyroid cancer to develop future strategies to effectively treat these patients and improve survival. Patients: Herein, we describe four patients with thyroid cancer treated with select

SUBMITTER: Cabanillas ME 

PROVIDER: S-EPMC7869871 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature